Intravitreal ranibizumab for retinopathy of prematurity: The ocular and systemic safety profile query.
作者信息
Al Kalbani Khulood, Ganesh Anuradha
机构信息
PGY5, Ophthalmology, Oman Medical Specialty Board, Seeb, Muscat, Oman.
Department of Ophthalmology, College of Medicine and Health Sciences, Sultan Qaboos University, Seeb, Muscat, Oman.
出版信息
Oman J Ophthalmol. 2023 Oct 18;16(3):397-398. doi: 10.4103/ojo.ojo_226_23. eCollection 2023 Sep-Dec.
Abstract
摘要
相似文献
1
Intravitreal ranibizumab for retinopathy of prematurity: The ocular and systemic safety profile query.玻璃体内注射雷珠单抗治疗早产儿视网膜病变：眼部和全身安全性概况探究。
Oman J Ophthalmol. 2023 Oct 18;16(3):397-398. doi: 10.4103/ojo.ojo_226_23. eCollection 2023 Sep-Dec.
2
Efficacy of ultra-low-dose (0.1 mg) ranibizumab intravitreal injection for treatment of prethreshold type 1 retinopathy of prematurity: A case series.超低剂量（0.1毫克）雷珠单抗玻璃体内注射治疗阈值前1型早产儿视网膜病变的疗效：病例系列
Eur J Ophthalmol. 2020 Jan;30(1):40-47. doi: 10.1177/1120672118812266. Epub 2018 Nov 15.
3
Results of intravitreal ranibizumab treatment for retinopathy of prematurity in infants.玻璃体内注射雷珠单抗治疗婴儿早产儿视网膜病变的结果。
Cutan Ocul Toxicol. 2017 Dec;36(4):356-361. doi: 10.1080/15569527.2017.1300160. Epub 2017 Mar 27.
4
Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity.早产儿视网膜病变经玻璃体腔内雷珠单抗注射治疗后的短期疗效。
Br J Ophthalmol. 2013 Jul;97(7):816-9. doi: 10.1136/bjophthalmol-2012-302276. Epub 2012 Dec 8.
5
Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.早产儿后部进展性视网膜病变治疗效果良好。
Eur J Ophthalmol. 2021 Jan;31(1):179-183. doi: 10.1177/1120672119886989. Epub 2019 Nov 13.
6
Low-dose ranibizumab administration in retinopathy of prematurity.早产儿视网膜病变中的低剂量雷珠单抗治疗。
Int Ophthalmol. 2022 May;42(5):1545-1552. doi: 10.1007/s10792-021-02145-w. Epub 2022 Jan 7.
7
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.雷珠单抗与激光治疗用于治疗极低出生体重早产儿视网膜病变（RAINBOW）：一项开放标签随机对照试验。
Lancet. 2019 Oct 26;394(10208):1551-1559. doi: 10.1016/S0140-6736(19)31344-3. Epub 2019 Sep 12.
8
Intravitreal ranibizumab as salvage therapy in an extremely low-birth-weight infant with rush type retinopathy of prematurity.玻璃体内注射雷珠单抗作为极低出生体重儿急进型早产儿视网膜病变的挽救治疗
Oman J Ophthalmol. 2012 Sep;5(3):184-6. doi: 10.4103/0974-620X.106103.
9
[The clinical study on intravitreous injection of ranibizumab for aggressive posterior retinopathy of prematurity].玻璃体内注射雷珠单抗治疗侵袭性早产儿视网膜病变的临床研究
Zhonghua Yan Ke Za Zhi. 2015 Nov;51(11):822-5.
10
Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity.玻璃体内注射雷珠单抗联合激光光凝治疗侵袭性早产儿视网膜病变
Case Rep Ophthalmol. 2012 Jan;3(1):136-41. doi: 10.1159/000338623. Epub 2012 Apr 30.
本文引用的文献
1
Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.玻璃体内注射阿柏西普与激光光凝治疗早产儿视网膜病变的疗效比较：FIREFLEYE 随机临床试验。
JAMA. 2022 Jul 26;328(4):348-359. doi: 10.1001/jama.2022.10564.
2
2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial.早产儿视网膜病变（ROP）经雷珠单抗与激光治疗后的 2 年疗效（RAINBOW 扩展研究）：一项开放性标签、随机对照临床试验的前瞻性随访。
Lancet Child Adolesc Health. 2021 Oct;5(10):698-707. doi: 10.1016/S2352-4642(21)00195-4. Epub 2021 Aug 13.
3
Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis.早产儿视网膜病变应用贝伐单抗治疗后的神经发育结局：系统评价和荟萃分析。
J Perinatol. 2021 Jun;41(6):1225-1235. doi: 10.1038/s41372-020-00884-9. Epub 2020 Dec 8.
4
Neurodevelopmental Outcomes after Bevacizumab Treatment for Retinopathy of Prematurity: A Meta-analysis.早产儿视网膜病变应用贝伐单抗治疗后的神经发育结局：Meta 分析。
Ophthalmology. 2021 Jun;128(6):877-888. doi: 10.1016/j.ophtha.2020.11.012. Epub 2020 Nov 16.
5
Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial.在RAINBOW试验中，雷珠单抗在早产儿视网膜病变患儿中的群体药代动力学和游离血管内皮生长因子药效学研究。
Transl Vis Sci Technol. 2020 Jul 29;9(8):43. doi: 10.1167/tvst.9.8.43. eCollection 2020 Jul.
6
Microvascular parameters evaluated with optical coherence tomography-angiography in children: comparison between preterm and full-term patients.光学相干断层扫描血管造影术评估儿童微血管参数：早产儿与足月儿的比较
Acta Ophthalmol. 2019 Nov;97(7):e1032-e1034. doi: 10.1111/aos.14131. Epub 2019 May 10.
7
Foveal microvascular anomalies on optical coherence tomography angiography and the correlation with foveal thickness and visual acuity in retinopathy of prematurity.早产儿视网膜病变中光学相干断层扫描血管造影的黄斑微血管异常及其与黄斑厚度和视力的相关性
Graefes Arch Clin Exp Ophthalmol. 2019 Jan;257(1):23-30. doi: 10.1007/s00417-018-4162-y. Epub 2018 Oct 25.
8
Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.比较不同雷珠单抗剂量治疗早产儿视网膜病变的安全性和有效性：一项随机临床试验。
JAMA Pediatr. 2018 Mar 1;172(3):278-286. doi: 10.1001/jamapediatrics.2017.4838.
9
Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.1 型早产儿视网膜病变玻璃体腔内注射贝伐单抗与激光治疗的 4 年随访：荧光血管造影结果。
Ophthalmology. 2018 Feb;125(2):218-226. doi: 10.1016/j.ophtha.2017.08.005. Epub 2017 Sep 1.
10
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF THE FOVEA IN CHILDREN BORN PRETERM.早产儿黄斑区的光学相干断层扫描血管造影
Retina. 2017 Dec;37(12):2289-2294. doi: 10.1097/IAE.0000000000001471.
Zotero 插件